Severely frail elderly patients do not need lipid-lowering drugs

ABSTRACT

After performing a systematic review, members of the Palliative and Therapeutic Harmonization (PATH) program and the Dalhousie Academic Detailing Service found that evidence does not support lipid-lowering therapy for severely frail elderly patients.

KEY POINTS

There is no reason to prescribe or continue statins for primary prevention in severely frail elderly patients, as these drugs are unlikely to provide benefit in terms of outcomes relevant to this population.

Statins are probably not necessary for secondary prevention in patients who are severely frail, although there may be extenuating circumstances for their use.

There is no reason to start or continue statins for heart failure, as there is insufficient evidence that they are effective for this indication in any population.

There is no reason to start or continue other lipid-lowering drugs in conjunction with statins.

As the frail elderly may be more vulnerable to the side effects of statins, lower doses may be more appropriate if these drugs are prescribed.

If there is concern regarding myopathy, a drug interaction, or other adverse effects, consider a trial of statin discontinuation.

Frail elderly patients are at high risk of adverse clinical outcomes, including those due to polypharmacy. Several groups tackle “deprescribing” by developing lists of medications that are potentially inappropriate for the elderly, such as the Beers or STOPP/START criteria.1–4

In contrast, our group (the Palliative and Therapeutic Harmonization [PATH] program and the Dalhousie Academic Detailing Service) has developed evidence-based, frailty-specific guidelines for treating hypertension5 and diabetes,6 in which we advocate less-stringent treatment targets and tapering or discontinuing medications, as needed.

The PATH program7 is a clinical approach that prioritizes the consideration of frailty when making treatment decisions. The Dalhousie Academic Detailing Service collaborates with the Nova Scotia Health Authority to research and develop evidence-informed educational messages about the treatment of common medical conditions.

Here, we address lipid-lowering therapy in this population.

CONSIDERING FRAILITY

Frailty is defined in several ways. The Fried model8,9 identifies frailty when 3 of the following characteristics are present: unintentional weight loss, exhaustion, muscle weakness, slow walking speed, or low levels of activity. The Clinical Frailty Scale10,11 and the Frailty Assessment for Care-planning Tool (FACT)3 use deficits in cognition, function, and mobility to define frailty. According to these scales, people are considered

Dr. Mallery and Dr. Moorhouse have disclosed partnership in Palliative and Therapeutic Harmonization Ltd.

doi:10.3949/ccjm.84a.15114
FRAILTY AND LIPID-LOWERING

severely frail when they require assistance with basic activities of daily living (such as bathing or dressing), owing to cognitive or physical deficits from any cause.

In reviewing the evidence, we consider five questions:

• What is the quality of the evidence? (Up to 48% of clinical practice guideline recommendations may be based on low-level evidence or expert opinion.12)
• How did the study population compare with the frail?
• Are study outcomes and potential benefits clinically relevant to those who are frail?
• How long did it take for the clinical benefit of a treatment to become apparent, and are the frail elderly likely to live that long?
• Have the harms of treatment been sufficiently considered?

WHAT IS THE QUALITY OF THE EVIDENCE?

We found no studies that specifically evaluated the benefit of lipid-lowering for severely frail older adults. Therefore, we examined randomized controlled trials that enrolled non-frail older adults,13–28 subgroup analyses of randomized controlled trials,29,30 meta-analyses that analyzed subgroups of elderly populations,31,32 and publications describing the study designs of randomized controlled trials.33–37

Most of the evidence comes from post hoc subgroup analyses of elderly populations. Although meta-analysis is commonly used to compare subgroups, the Cochrane handbook and others consider subgroup comparisons observational by nature.38,39 (See Table 1 for lipid-lowering studies discussed in this article.)

Studies of statins for primary prevention of cardiovascular disease

For evidence of benefit from lipid-lowering for primary prevention (ie, to reduce the risk of cardiovascular events in patients with no known cardiovascular disease at baseline but at increased risk), we reviewed the meta-analysis conducted by the Cholesterol Treatment Trialists’ (CTT) Collaborators.32 Since this meta-analysis included the major trials that enrolled elderly patients, individual publications of post hoc, elderly subgroups were, for the most part, not examined individually. The exception to this approach was a decision to report on the PROSPER13 and JUPITER28 trials separately, because PROSPER is the most representative of the elderly population and JUPITER reached the lowest LDL-C of primary prevention trials published to date and included a large elderly subgroup (n = 5,695).

Savarese et al40 evaluated the benefits of statins for older adults who did not have established cardiovascular disease. We did not report on this meta-analysis, as not all of the subjects that populated the meta-analysis were representative of a typical prevention population. For instance, in the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm,41 14% of the subjects had had a previous stroke or transient ischemic attack. In the Antihypertensive and Lipid-Lowering Treatment Trial,42 16% of the population had a family history of premature coronary heart disease.

In addition, all the trials in the Savarese meta-analysis were also included in the CTT meta-analysis.32 The CTT reports on baseline risk using patient-level data stratified by age and risk, which may be more relevant to the question of primary prevention for older adults, as highlighted in our review.

PROSPER (Prospective Study of Pravastatin in the Elderly at Risk),13 a well-conducted, double-blind, randomized controlled trial with low probability of bias, compared pravastatin 40 mg and placebo. It was the only study that specifically enrolled older adults, with prespecified analysis of primary and secondary prevention subgroups. The primary prevention subgroup accounted for 56% of the 5,084 participants.

JUPITER (Justification for the Use of Statins in Prevention)28 compared rosuvastatin 20 mg and placebo in 17,802 participants. All had low-density lipoprotein cholesterol (LDL-C) levels below 3.4 mmol/L (130 mg/dL) and elevated levels of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP), ie, 2 mg/L or higher. Subsequently, Glynn et al performed a post hoc, exploratory subgroup analysis of elderly participants (N = 5,695).29

The JUPITER trial had several limitations.43,44 The planned follow-up period was 5 years, but the trial was stopped early at 1.9 years, after a statistically significant difference was detected in the primary composite
outcome of reduction in all vascular events. Studies that are stopped early may exaggerate positive findings.45

Further, JUPITER’s patients were a select group, with normal LDL-C levels, elevated hsCRP values, and without diabetes. Of 90,000 patients screened, 72,000 (80%) did not meet the inclusion criteria and were not enrolled. This high rate of exclusion limits the generalizability of study findings beyond the shortcomings of post hoc subgroup analysis.

The meta-analysis performed by the CTT Collaborators32 used individual participant data from large-scale randomized trials of lipid-modifying treatment. This analysis was specific to people at low risk of vascular disease. In a supplementary appendix, the authors described the reduction in major vascular events for each 1.0 mmol/L decrease in LDL-C in three age categories: under age 60, ages 61 to 70, and over age 70.

The authors also stratified the results by risk category and provided information about those with a risk of major vascular events of less than 20%, which would be more representative of a purer primary prevention population.

For the elderly subgroup at low risk, the CTT Collaborators32 only reported a composite of major vascular events (coronary death, nonfatal myocardial infarction [MI], ischemic stroke, or revascularization) and did not describe individual outcomes, such as prevention of coronary heart disease.

Study results are based on postrandomization findings and therefore may be observational, not experimental.46

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Population</th>
<th>Mean follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROSPER13</td>
<td>Randomized controlled trial</td>
<td>Pravastatin 40 mg vs placebo N = 5,804, mean age 75 Primary and secondary prevention Mini-Mental State score ≥ 24 of 30</td>
<td>3.2 years</td>
</tr>
<tr>
<td>JUPITER28,29</td>
<td>Randomized controlled trial</td>
<td>Rosuvastatin 20 mg vs placebo N = 5,695 (elderly subgroup) Median age 74 Primary prevention</td>
<td>1.9 years (stopped prematurely)</td>
</tr>
<tr>
<td>CTT32</td>
<td>Meta-analysis</td>
<td>Not applicablea</td>
<td>Variable</td>
</tr>
<tr>
<td>Afilalo et al31</td>
<td>Meta-analysis</td>
<td>N = 19,569 Age range 65–82 Secondary prevention</td>
<td>4.9 years</td>
</tr>
<tr>
<td>SPARCL27,30</td>
<td>Randomized controlled trial</td>
<td>Atorvastatin 80 mg vs placebo N = 2,249 (subgroup age ≥ 65) Mean age of subgroup 72.4 Secondary prevention</td>
<td>4.9 years</td>
</tr>
<tr>
<td>GISSI-HF25</td>
<td>Randomized controlled trial</td>
<td>Rosuvastatin 10 mg vs placebo N = 4,574, mean age 68 Heart failure, NYHA class II to IV</td>
<td>3.9 years (median)</td>
</tr>
<tr>
<td>CORONA26</td>
<td>Randomized controlled trial</td>
<td>Rosuvastatin 10 mg vs placebo N = 5,011, mean age 73 Heart failure, NYHA class II to IV</td>
<td>2.7 years</td>
</tr>
</tbody>
</table>

aThe CTT meta-analysis presents the effects of statins on major vascular events per annum, per 1.0 mmol/L reduction in LDL-C according to 5-year risk at baseline. The analysis in patients > 70 years old includes a total of 2,952 events in the statin group and 3,385 events in the control group (or a total of 6,337 events.

CORONA = Controlled Rosuvastatin Multinational Trial in Heart Failure; CTT = Cholesterol Treatment Trialists; GISSI-HF= Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca Heart Failure; JUPITER = Justification for the Use of Statins in Prevention; NYHA = New York Heart Association; PROSPER = Prospective Study of Pravastatin in the Elderly at Risk; SPARCL = Stroke Prevention by Aggressive Reduction in Cholesterol Levels
**FRAILTY AND LIPID-LOWERING**

Studies of statins for secondary prevention of cardiovascular disease

The aim of secondary prevention is to reduce the risk of recurrent cardiovascular events in patients who already have cardiovascular disease.

To address the question of whether statins reduce cardiovascular risk, we reviewed:

PROSPER, which included a pre-planned analysis of the secondary prevention population.

Afilalo et al, who performed a meta-analysis of the elderly subgroups of nine major secondary prevention studies (19,569 patients) using published and unpublished data.

To address the question of whether statins benefit individuals with heart failure, we found two relevant studies:

GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca Heart Failure) and CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure), which were large, international, well-conducted randomized controlled trials that examined statin use in heart failure.

To answer the question of whether statins benefit individuals after a stroke or transient ischemic attack, we found one relevant study:

SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels), which evaluated the benefit of statins in older adults with a history of stroke or transient ischemic attack. It was a prospective, double-blind, placebo-controlled, international trial conducted at 205 centers. One to 6 months after their cerebrovascular event, patients were randomized to receive either atorvastatin 80 mg or placebo. Given the young age of patients in this trial (mean age 63), we also reviewed a post hoc subgroup analysis of the elderly patients in SPARCL (age > 65).

**ARE STUDY OUTCOMES CLINICALLY RELEVANT TO THOSE WHO ARE FRAIL?**

Because baseline cardiovascular risk increases with age, the elderly should, in theory, experience greater absolute benefit from lipid-lowering. However, there is uncertainty about whether this is true in practice.

Some, but not all, epidemiologic studies show a weaker relationship between cholesterol levels and cardiovascular morbidity and mortality rates in older compared to younger adults. This may be because those with high cholesterol levels die before they get old (time-related bias), or because those with life-threatening illness may have lower cholesterol levels. In addition, classic risk factors such as age, sex, systolic blood pressure, cholesterol values, diabetes, smoking, and left ventricular hypertrophy on electrocardiography may have less power to predict cardiovascular risk among older patients.

The goal of treatment in frailty is to prevent further disability or improve quality of life.

Participants in the studies we reviewed were generally younger and healthier than those who are frail, with mean ages of about 75 or less (Table 1).

PROSPER was the most representative study, as it specifically enrolled older adults, albeit without frailty, and excluded people with poor cognitive function as defined by a Mini Mental State Examination score less than 24.

JUPITER enrolled a select population, as described above. The median age in the elderly subgroup was 74 (interquartile range 72–78). The Afilalo et al meta-analysis primarily included studies of young-elderly patients, with a mean age of less than 70. PROSPER was an exception.

The GISSI-HF study, which examined the benefit of statins in heart failure, described their study population as frail, although the mean age was only 68. Compared with those in GISSI-HF, the CORONA patients with heart failure were older (mean age 73) and had more severe heart failure. Accordingly, it is possible that many of the CORONA participants were frail.

**HOW DID THE STUDY POPULATION COMPARE WITH THOSE WHO ARE FRAIL?**

Frail older adults are almost always excluded from large-scale clinical trials, leading to uncertainty about whether the conclusions can be applied to those with advanced frailty.

Although age is an imperfect proxy measure of frailty, we consider the age of the study population as well as their comorbidities.

No studies have specifically evaluated the benefit of lipid-lowering for severely frail older adults
life. Therefore, meaningful outcomes for lipid-lowering therapy should include symptomatic nonfatal MI and its associated morbidity (eg, heart failure and persistent angina) or symptomatic nonfatal stroke leading to disability. Outcomes without sustained clinical impact, such as transient ischemic attack, nondisabling stroke, or silent MI, while potentially important in other populations, are less relevant in severe frailty. Notably, in many statin studies, outcomes include asymptomatic heart disease (eg, silent MI and “suspected events”) and nondisabling stroke (eg, mild stroke, transient ischemic attack). When symptomatic outcomes are not reported separately, the impact of the reported benefit on quality of life and function is uncertain.

The outcome of all-cause mortality is generally recognized as a gold standard for determining treatment benefit. However, since advanced frailty is characterized by multiple competing causes for mortality, a reduction in all-cause mortality that is achieved by addressing a single issue in nonfrail populations may not extend to the frail.

To more fully understand the impact of lipid-lowering therapy on quality of life and function, we examined the following questions:

**Do statins as primary prevention reduce symptomatic heart disease?**

Outcomes for coronary heart disease from PROSPER and JUPITER are summarized in Table 2.

**PROSPER.** In the PROSPER primary prevention group, statin therapy did not reduce the combined outcome of coronary heart disease death and nonfatal MI.

**The JUPITER trial** demonstrated a statistically significant benefit for preventing MI

### TABLE 2

**Coronary heart disease outcomes**

<table>
<thead>
<tr>
<th>Trial and outcome</th>
<th>Event rate</th>
<th></th>
<th>Absolute risk reduction</th>
<th>Relative risk reduction</th>
<th>Number needed to treat (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary prevention studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROSPER(^{13})</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary heart disease death and nonfatal myocardial infarction</td>
<td>8.8%</td>
<td>7.9%</td>
<td>.401</td>
<td>0.9%</td>
<td>9%</td>
</tr>
<tr>
<td>JUPITER(^{28,29})</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>1.1%</td>
<td>0.6%</td>
<td>.046</td>
<td>0.5%</td>
<td>45%</td>
</tr>
<tr>
<td><strong>Secondary prevention studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROSPER(^{13})</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary heart disease death and nonfatal myocardial infarction (includes definite and suspect events)</td>
<td>16.8%</td>
<td>12.7%</td>
<td>.004</td>
<td>4.1%</td>
<td>24%</td>
</tr>
<tr>
<td><strong>Afilalo et al meta-analysis(^{31})</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonfatal myocardial infarction</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>26%(^{b})</td>
</tr>
<tr>
<td><strong>Combined primary and secondary prevention studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROSPER(^{13})</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonfatal myocardial infarction (excluding silent and unrecognized events)</td>
<td>4.3%</td>
<td>3.4%</td>
<td>.099</td>
<td>0.9%</td>
<td>20%</td>
</tr>
</tbody>
</table>

\(^{a}\) Not statistically significant (P > .05) and numbers needed to treat (NNT) not calculated on these results. NNT calculated on raw numbers if not provided in publication. See Table 1 for duration of treatment required for NNT.

\(^{b}\) Afilalo et al provided relative risk reductions and NNTs in their publication. Absolute risk reductions not calculated on meta-analytic outcomes.

CI = confidence interval; NA = not available; NS = not statistically significant
in the elderly subpopulation (ages 70–97), but the number needed to treat was high (211 for 2 years), with a wide confidence interval (CI) (95% CI 106–32,924). The trial did not adequately differentiate between symptomatic and asymptomatic events, making it difficult to determine outcome relevance. Also, due to the methodologic limitations of JUPITER as described above, its results should be interpreted with caution.

The CTT Collaborators did not report individual outcomes (eg, coronary heart disease) for the elderly low-risk subgroup and, therefore, this meta-analysis does not answer the question of whether statins reduce symptomatic heart disease in primary prevention populations.

Taken together, these findings do not provide convincing evidence that statin therapy as primary prevention reduces the incidence of symptomatic heart disease for severely frail older adults.

Do statins as secondary prevention reduce symptomatic heart disease?

Most studies defined secondary prevention narrowly as treatment for patients with established coronary artery disease. For instance, in the Afilalo et al meta-analysis, the small number of studies that included individuals with other forms of vascular disease (such as peripheral vascular disease) enrolled few participants with noncardiac conditions (eg, 29% in PROSPER and 13% in the Heart Protection Study20).

Therefore, any evidence of benefit for secondary prevention demonstrated in these studies is most applicable to patients with coronary heart disease, with less certainty for those with other forms of cardiovascular disease.

In PROSPER, the secondary prevention group experienced benefit in the combined outcome of coronary heart disease death or nonfatal MI. In the treatment group, 12.7% experienced this outcome compared with 16.8% with placebo, an absolute risk reduction of 4.1% in 3 years (P = .004, number needed to treat 25, 95% CI 15–77). This measure includes coronary heart disease death, an outcome that may not be generalizable to those who are frail. In addition, the outcome of nonfatal MI includes both symptomatic and suspected events. As such, there is uncertainty whether the realized benefit is clinically relevant to frail older adults.

The Afilalo et al meta-analysis showed that the number needed to treat to prevent one nonfatal MI was 38 (95% CI 16–118) over 5 years (Table 2). However, this outcome included both symptomatic and asymptomatic (silent) events.

Based on the available data, we conclude that it is not possible to determine whether statins reduce symptomatic heart disease as secondary prevention for older adults who are frail.

Do statins reduce heart disease in combined populations?

In the combined primary and secondary population from PROSPER, pravastatin decreased the risk of nonfatal symptomatic MI from 4.3% in the placebo group to 3.4%, a relatively small reduction in absolute risk (0.9%) and not statistically significant by our chi-square calculation (P = .099).

Do statins prevent a first symptomatic stroke in people with or without preexisting cardiovascular disease?

Preventing strokes that cause functional decline is an important outcome for the frail elderly. Stroke outcomes from PROSPER, JUPITER, and the Afilalo et al meta-analysis are summarized in Table 3.

For primary prevention:

In PROSPER (primary prevention), there was no statistically significant benefit in the combined outcome of fatal and nonfatal stroke or the single outcome of transient ischemic attack after 3.2 years.

JUPITER, in contrast, found that rosuvastatin 20 mg reduced strokes in primary prevention, but the absolute benefit was small. In 2 years, 0.8% of the treatment group had strokes, compared with 1.4% with placebo, an absolute risk reduction of 0.6% (P = .023, number needed to treat 161, 95% CI 86–1,192).

Neither PROSPER nor JUPITER differentiated between disabling and nondisabling strokes.

For secondary prevention:

In PROSPER (secondary prevention), there was no statistically significant benefit in the combined outcome of fatal and nonfatal stroke or the single outcome of transient isch-
emic attack after 3.2 years.

The Afilalo et al secondary prevention meta-analysis demonstrated a 25% relative reduction in stroke (relative risk 0.75, 95% CI 0.56–0.94, number needed to treat 58, 95% CI 27–177).\textsuperscript{31}

Notably, the stroke outcome in Afilalo included both disabling and nondisabling strokes. For example, in the Heart Protection Study,\textsuperscript{20} the largest study in the Afilalo et al meta-analysis, approximately 50% of nonfatal, classifiable strokes in the overall study population (ie, both younger and older patients) were not disabling. Including disabling and nondisabling strokes in a composite outcome confounds the clinical meaningfulness of these findings in frailty, as the number needed to treat to prevent one disabling stroke cannot be calculated from the data provided.

Do statins prevent a second (symptomatic) stroke in people with a previous stroke?

SPARCL\textsuperscript{27} (Table 3) examined the question of whether statins decrease the risk of recurrent ischemic stroke for patients with a prior history of stroke or transient ischemic attack. There was a statistically significant reduction in the primary composite outcome of fatal and

<table>
<thead>
<tr>
<th>TABLE 3</th>
<th>Stroke outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trial and outcome</strong></td>
<td>Event rate</td>
</tr>
<tr>
<td><strong>Placebo</strong></td>
<td><strong>Statin</strong></td>
</tr>
<tr>
<td>Primary prevention studies</td>
<td></td>
</tr>
<tr>
<td>PROSPER\textsuperscript{13}</td>
<td></td>
</tr>
<tr>
<td>Fatal or nonfatal stroke</td>
<td>3.7%</td>
</tr>
<tr>
<td>Transient ischemic attack</td>
<td>2.3%</td>
</tr>
<tr>
<td>JUPITER\textsuperscript{28,29}</td>
<td></td>
</tr>
<tr>
<td>Stroke (percent based on raw number of events)</td>
<td>1.4%</td>
</tr>
<tr>
<td>Secondary prevention studies</td>
<td></td>
</tr>
<tr>
<td>PROSPER\textsuperscript{13}</td>
<td></td>
</tr>
<tr>
<td>Fatal and nonfatal stroke</td>
<td>5.5%</td>
</tr>
<tr>
<td>Transient ischemic attack</td>
<td>5.1%</td>
</tr>
<tr>
<td>Afilalo meta-analysis\textsuperscript{31}</td>
<td></td>
</tr>
<tr>
<td>Stroke (disabling and nondisabling)</td>
<td>NA</td>
</tr>
<tr>
<td>SPARCL\textsuperscript{27}</td>
<td></td>
</tr>
<tr>
<td>Fatal or nonfatal stroke</td>
<td>13.1%</td>
</tr>
<tr>
<td>Nonfatal stroke</td>
<td>11.8%</td>
</tr>
<tr>
<td>SPARCL subgroup ≥ 65\textsuperscript{30}</td>
<td></td>
</tr>
<tr>
<td>Fatal or nonfatal stroke</td>
<td>16.2%</td>
</tr>
<tr>
<td>SPARCL subgroup &lt; 65\textsuperscript{30}</td>
<td></td>
</tr>
<tr>
<td>Fatal or nonfatal stroke</td>
<td>10.5%</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Numbers for relative risk reduction are rounded to the nearest whole number

\textsuperscript{b} Not statistically significant (P > .05) and numbers needed to treat not calculated on these results. Number needed to treat (NNT) calculated on raw numbers if not provided in publication. See Table 1 for duration of treatment required for NNT. CI = confidence interval

\textsuperscript{c} Afilalo et al provided relative risk reductions and NNT. Absolute risk reductions not calculated on meta-analytic outcomes.
nonfatal stroke, with 11.2% of the treatment group and 13.1% of the placebo group experiencing this outcome, an absolute risk reduction of 1.9% at 5 years ($P = .03$; number needed to treat 52, 95% CI 26–1,303). However, the difference in nonfatal stroke, which is the outcome of interest for frailty (since mortality has uncertain relevance), was not statistically significant (10.4% with treatment vs 11.8% with placebo, $P = .11$).

An exploratory subgroup analysis of SPARCL patients based on age showed a smaller, nonsignificant reduction in the primary end point of fatal and nonfatal stroke in the group over age 65 (relative risk 0.90, 95% confidence interval 0.73–1.11, $P = .33$) compared with the younger group (age < 65) (relative risk 0.74, 95% CI 0.57–0.96, $P = .02$).

The applicability of these results to the frail elderly is uncertain, since the subgroup analysis was not powered to determine outcomes based on age stratification and there were differences between groups in characteristics such as blood pressure and smoking status. In addition, the outcome of interest, nonfatal stroke, is not provided for the elderly subgroup.

In conclusion, in both primary and secondary prevention populations, the evidence that statins reduce nonfatal, symptomatic stroke rates for older adults is uncertain.

**Do statins decrease all-cause mortality for primary or secondary prevention?**

Due to competing risks for death, the outcome of mortality may not be relevant to those who are frail; however, studies showed the following:

- **For primary prevention**, there was no decrease in mortality in PROSPER or in the elderly subgroup of JUPITER.

- **For secondary prevention**, an analysis of PROSPER trial data by Afilalo et al showed a significant 18% decrease in all-cause mortality (relative risk 0.82, 95% CI 0.69–0.98) using pravastatin 40 mg.

- A decrease in all-cause mortality with statins was also reported in the pooled result of the Afilalo et al meta-analysis.

**What are the reported composite outcomes for primary and secondary prevention?**

While we were most interested in the symptomatic outcomes described above, we recognize that the small numbers of events make it difficult to draw firm conclusions. Therefore, we also considered composite primary outcomes, even though most included multiple measures that have varying associations with disability and relevancy to frail older adults.

**For primary prevention**, in the PROSPER preplanned subgroup analysis, there was no statistical benefit for any outcome, including the primary composite measure. In contrast, the elderly subgroup in the JUPITER trial showed a treatment benefit with rosuvastatin 20 mg compared with placebo for the primary composite outcome of MI, stroke, cardiovascular death, hospitalization for unstable angina, or revascularization. The number needed to treat for 2 years was 62 (95% CI 39–148).

In the CTT meta-analysis, patients at all levels of baseline risk showed benefit up to age 70. However, there was no statistically significant benefit in the composite primary outcome of coronary deaths, nonfatal myocardial infarction, ischemic stroke, or revascularization in the population most representative of elderly primary prevention—those who were more than 70 years old with a 5-year baseline risk of less than 20%.

**For secondary prevention**, in PROSPER, the subpopulation of patients treated for secondary prevention experienced benefit in the primary composite outcome of coronary heart disease death, nonfatal MI, or fatal or nonfatal stroke, achieving a 4% absolute risk reduction with a number needed to treat of 23 (95% CI 14–81) over 3 years.

**Do statins decrease disability?**

PROSPER was the only study that reported on disability. Compared with placebo, pravastatin did not decrease disability in the total population as measured by basic and instrumental activities of daily living scales.

**Do statins help patients with heart failure?**

Neither GISSI-HF nor CORONA found significant benefit from rosuvastatin 10 mg, despite LDL-C lowering of 27% in GISSI-HF and 45% in CORONA.

**Do ezetimibe or other nonstatin lipid-lowering agents improve outcomes?**

There is no definitive evidence that ezetimibe provides clinically meaningful benefit as a single agent.
For combination therapy, the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)\textsuperscript{53} showed that adding ezetimibe 10 mg to simvastatin 40 mg after an acute coronary syndrome reduced the risk of nonfatal myocardial infarction compared with simvastatin monotherapy (event rate 12.8% vs 14.4%; hazard ratio 0.87, 95% CI 0.80–0.95; \(P = .002\)) for a population with a mean age of 64. The risk of any stroke was also reduced; strokes occurred in 4.2% of those receiving combination therapy vs 4.8% with monotherapy (hazard ratio 0.86, 95% CI 0.73–1.00, \(P = .05\)). After a median of 6 years, 42% of patients in each group had discontinued treatment. Given the very specific clinical scenario of acute coronary syndrome and the young age of the patients in this trial, we do not think that this study justifies the use of ezetimibe for severely frail older adults.

There is no evidence that other combinations (ie, a statin plus another lipid-lowering drug) improve clinical outcomes for either primary or secondary prevention in any population.\textsuperscript{54}

\section*{WILL FRAIL PATIENTS LIVE LONG ENOUGH TO BENEFIT?}

It is often difficult to determine the number of years that are needed to achieve benefit, as most trials do not provide a statistical analysis of varying time frames.

The PROSPER trial\textsuperscript{13} lasted 3.2 years. From the Kaplan-Meier curves in PROSPER, we estimate that it took about 1.5 years to achieve a 1% absolute risk reduction and 2.5 years for a 2% absolute risk reduction in coronary heart disease death and nonfatal MI in the combined primary and secondary groups.

JUPITER\textsuperscript{28} was stopped early at 1.9 years. The Afilalo et al meta-analysis\textsuperscript{31} was based on follow-up over 4.9 years.

IMPROVE-IT\textsuperscript{53} reported event rates at 7 years. The authors note that benefit in the primary composite outcome appeared to emerge at 1 year, although no statistical support is given for this statement and divergence in the Kaplan-Meier curves is not visually apparent.

The duration of other studies ranged between 2.7 and 4.9 years (Table 1).\textsuperscript{26-28}

It has been suggested that statins should be considered for elderly patients who have a life expectancy of at least 5 years.\textsuperscript{3} However, many older adults have already been taking statins for many years, which makes it difficult to interpret the available timeframe evidence.

In a multcenter, unblinded, randomized trial,\textsuperscript{55} statins were either stopped or continued in older adults who had a short life expectancy and a median survival of approximately 7 months. Causes of death were evenly divided between cancer and noncancer diagnoses, and 22% of the patients were cognitively impaired. Discontinuing statin therapy did not increase mortality or cardiovascular events within 60 days. Nevertheless, stopping statin therapy did not achieve noninferiority for the primary end point, the proportion of participants who died within 60 days. Statin discontinuation was associated with improved quality of life, although the study was not blinded, which could have influenced results.

\section*{HAVE THE HARMS BEEN SUFFICIENTLY CONSIDERED?}

Frail older adults commonly take multiple medications and are more vulnerable to adverse events.\textsuperscript{56}

Many statins require dose reduction with severe renal impairment (creatinine clearance < 30 mL/min/1.73 m\textsuperscript{2}), which would be a common consideration in severely frail older adults.

\subsection*{Myopathy}

Myopathy, which includes myalgias and muscle weakness, is a statin-related adverse event that can impair quality of life. Myopathy typically develops within the first 6 months but can occur at any time during statin treatment.\textsuperscript{57} When muscle-related adverse effects occur, they may affect the elderly more significantly, particularly their ability to perform activities of daily living, rise from a chair, or mobilize independently. Another concern is that older adults with dementia may not be able to accurately report muscle-related symptoms.

It is difficult to ascertain the true prevalence of myopathy, especially in advanced age and frailty. Randomized controlled trials report incidence rates of 1.5% to 5%, which is comparable to placebo.\textsuperscript{57,58} However, inconsistent definitions of myopathy and exclusion of subjects with previous statin intolerance or adverse effects during run-in periods limit interpretabil-
FRAILTY AND LIPID-LOWERING

ity. Clinical experience suggests that muscle complaints may be relatively common.

Advanced age, female sex, low body mass index, and multisystem disease are all associated with frailty and have also been described as risk factors for statin-associated muscle syndromes. Physiologic changes associated with frailty, such as reduced muscle strength, decreased lean body mass, impaired functional mobility, decreased reserve capacity, and altered drug metabolism may increase the risk and severity of myopathy.

Adverse cognitive events
Meta-analyses of randomized clinical trials and narrative reviews find no definitive relationship between statin therapy and adverse cognitive events. Nevertheless, there have been case reports of memory loss associated with the use of statins, and the US Food and Drug Administration has issued a warning that statins have been associated with memory loss and confusion.

It may be difficult to determine whether a statin is causing or aggravating cognitive symptoms among individuals with dementia without a trial withdrawal of the drug.

OUR RECOMMENDATIONS
The recommendations below are intended for adults with severe or very severe frailty (ie, a score of 7 or 8 on the Clinical Frailty Scale or FACT) and therefore apply to most older adults living in long-term care facilities.

Primary prevention
There is no reason to prescribe or continue statins for primary prevention, as it is unlikely that they would provide benefit for outcomes that are relevant in this population.

Secondary prevention
Statin treatment is probably not necessary for secondary prevention in those with severe frailty, although there may be extenuating circumstances that justify statin use.

Heart failure
There is no reason to start or continue statins for heart failure, as there is insufficient evidence that they are effective for this indication in any population.

Ezetimibe
There is no evidence that ezetimibe reduces cardiovascular events in any population when used as monotherapy. For a select population with acute coronary syndromes, ezetimibe has a modest effect. Given the very specific clinical scenario of acute coronary syndrome, we do not think that the available evidence justifies the use of ezetimibe for severely frail older adults.

Agents other than ezetimibe combined with statins
There is no reason to start or continue other lipid-lowering drugs in conjunction with statins.

Statin dosing
As statin adverse effects have the potential to increase with advancing age and frailty, lower doses may be appropriate.

Adverse events
Consider stopping statins on a trial basis if there is concern regarding myopathy, drug interactions, or other adverse effects.

BOTTOM LINE: DO STATINS IMPROVE QUALITY OF LIFE OR FUNCTION?
In primary prevention for older adults, there is doubt that statins prevent cardiovascular disease and stroke-related events because the main study involving the elderly did not show a benefit in the primary prevention subgroup. Additionally, there is no conclusive evidence that statin treatment decreases mortality in primary prevention.

There is insufficient information to determine whether the frail elderly should receive statins for secondary prevention. Although there is evidence that treatment decreases measures of coronary heart disease and stroke, it is unclear whether it improves quality of life or function for those who are frail. To answer this question, we need more information about whether reported outcomes (such as stroke and MI) are associated with disability, which is not provided in many of the studies we reviewed. When disability was specifically considered in the PROSPER trial for the combined population of primary and secondary prevention, treatment with statins had no impact on basic and instrumental activities of daily living.

We conclude that medications should be used in this population only if they improve quality of life or function.
Some experts may not agree with our interpretation of the complex evidence presented in this article. Others may ask, “What is the harm in using statins, even if there is no definitive benefit?” However, the harms associated with statin therapy for the frail are poorly defined. In the face of these uncertainties and in the absence of definitive improvement in quality of life, we believe that “less is more” in the context of severe frailty.

The cost of medications should also be considered, especially in long-term care facilities, where there is an added expense of drug administration that diverts human resources away from interactions that are more congruent with respecting the lifestage of frailty.

Careful review of evidence before applying clinical practice guidelines to those who are frail should become the norm. When considering treatment of frail patients, the five questions described in this review shed light on the applicability of clinical trial evidence. Therapies that are highly effective in healthier populations may be less effective when individuals are severely frail. Accordingly, we propose that medications should only be used if they improve quality of life or function.

REFERENCES